148 related articles for article (PubMed ID: 37506334)
1. Responding to changes in the unregulated drug supply: the need for a dynamic approach to drug checking technologies.
Bhuiyan I; Tobias S; Ti L
Am J Drug Alcohol Abuse; 2023 Nov; 49(6):685-690. PubMed ID: 37506334
[TBL] [Abstract][Full Text] [Related]
2. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods.
Laing MK; Ti L; Marmel A; Tobias S; Shapiro AM; Laing R; Lysyshyn M; Socías ME
Int J Drug Policy; 2021 Jul; 93():103169. PubMed ID: 33627302
[TBL] [Abstract][Full Text] [Related]
3. Examining fentanyl and its analogues in the unregulated drug supply of British Columbia, Canada using drug checking technologies.
Crepeault H; Socias ME; Tobias S; Lysyshyn M; Custance A; Shapiro A; Ti L
Drug Alcohol Rev; 2023 Mar; 42(3):538-543. PubMed ID: 36423900
[TBL] [Abstract][Full Text] [Related]
4. Drug checking as a potential strategic overdose response in the fentanyl era.
Laing MK; Tupper KW; Fairbairn N
Int J Drug Policy; 2018 Dec; 62():59-66. PubMed ID: 30359874
[TBL] [Abstract][Full Text] [Related]
5. A qualitative assessment of key considerations for drug checking service implementation.
Grace Rose C; Pickard AS; Kulbokas V; Hoferka S; Friedman K; Epstein J; Lee TA
Harm Reduct J; 2023 Oct; 20(1):151. PubMed ID: 37848875
[TBL] [Abstract][Full Text] [Related]
6. Beyond a spec: assessing heterogeneity in the unregulated opioid supply.
Gozdzialski L; Louw R; Kielty C; Margolese A; Poarch E; Sherman M; Cameron F; Gill C; Wallace B; Hore D
Harm Reduct J; 2024 Mar; 21(1):63. PubMed ID: 38491435
[TBL] [Abstract][Full Text] [Related]
7. A new quantitative drug checking technology for harm reduction: Pilot study in Vancouver, Canada using paper spray mass spectrometry.
Borden SA; Saatchi A; Vandergrift GW; Palaty J; Lysyshyn M; Gill CG
Drug Alcohol Rev; 2022 Feb; 41(2):410-418. PubMed ID: 34347332
[TBL] [Abstract][Full Text] [Related]
8. Variability in the unregulated opioid market in the context of extreme rates of overdose.
Larnder A; Saatchi A; Borden SA; Moa B; Gill CG; Wallace B; Hore D
Drug Alcohol Depend; 2022 Jun; 235():109427. PubMed ID: 35405459
[TBL] [Abstract][Full Text] [Related]
9. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications.
Bowles JM; McDonald K; Maghsoudi N; Thompson H; Stefan C; Beriault DR; Delaney S; Wong E; Werb D
Harm Reduct J; 2021 Oct; 18(1):104. PubMed ID: 34645480
[TBL] [Abstract][Full Text] [Related]
10. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting.
Tupper KW; McCrae K; Garber I; Lysyshyn M; Wood E
Drug Alcohol Depend; 2018 Sep; 190():242-245. PubMed ID: 30064061
[TBL] [Abstract][Full Text] [Related]
11. A survey of North American drug checking services operating in 2022.
Park JN; Tardif J; Thompson E; Rosen JG; Lira JAS; Green TC
Int J Drug Policy; 2023 Nov; 121():104206. PubMed ID: 37797571
[TBL] [Abstract][Full Text] [Related]
12. Portable gas chromatography-mass spectrometry in drug checking: Detection of carfentanil and etizolam in expected opioid samples.
Gozdzialski L; Aasen J; Larnder A; Ramsay M; Borden SA; Saatchi A; Gill CG; Wallace B; Hore DK
Int J Drug Policy; 2021 Nov; 97():103409. PubMed ID: 34392112
[TBL] [Abstract][Full Text] [Related]
13. Rapid and accurate etizolam detection using surface-enhanced Raman spectroscopy for community drug checking.
Gozdzialski L; Rowley A; Borden SA; Saatchi A; Gill CG; Wallace B; Hore DK
Int J Drug Policy; 2022 Apr; 102():103611. PubMed ID: 35151084
[TBL] [Abstract][Full Text] [Related]
14. Point-of-care community drug checking technologies: an insider look at the scientific principles and practical considerations.
Gozdzialski L; Wallace B; Hore D
Harm Reduct J; 2023 Mar; 20(1):39. PubMed ID: 36966319
[TBL] [Abstract][Full Text] [Related]
15. Recommendations from people who use drugs in Philadelphia, PA about structuring point-of-care drug checking.
Reed MK; Borne E; Esteves Camacho T; Kelly M; Rising KL
Harm Reduct J; 2024 Jan; 21(1):26. PubMed ID: 38287409
[TBL] [Abstract][Full Text] [Related]
16. Results from a mobile drug checking pilot program using three technologies in Chicago, IL, USA.
Karch L; Tobias S; Schmidt C; Doe-Simkins M; Carter N; Salisbury-Afshar E; Carlberg-Racich S
Drug Alcohol Depend; 2021 Nov; 228():108976. PubMed ID: 34536717
[TBL] [Abstract][Full Text] [Related]
17. Effect of witnessing an overdose on the use of drug checking services among people who use illicit drugs in Vancouver, Canada.
Beaulieu T; Hayashi K; Nosova E; Milloy MJ; DeBeck K; Wood E; Kerr T; Ti L
Am J Drug Alcohol Abuse; 2020 Jul; 46(4):506-511. PubMed ID: 31983241
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl Concentration in Drug Checking Samples and Risk of Overdose Death in Vancouver, Canada.
Kennedy MC; Dong H; Tobias S; Buxton JA; Lysyshyn M; Tupper KW; Ti L
Am J Prev Med; 2024 Jan; 66(1):10-17. PubMed ID: 37633426
[TBL] [Abstract][Full Text] [Related]
19. Enhancing drug checking services for supply monitoring: perspectives on implementation in syringe service programs in the USA.
Moon KJ; Whitehead HD; Trinh A; Hasenstab KA; Hayes KL; Stanley D; Carter B; Barclay R; Lieberman M; Nawaz S
Harm Reduct J; 2024 Jan; 21(1):11. PubMed ID: 38218980
[TBL] [Abstract][Full Text] [Related]
20. Costing analysis of a point-of-care drug checking program in Rhode Island.
Cepeda JA; Thompson E; Ujeneza M; Tardif J; Walsh T; Morales A; Rosen JG; Green TC; Park JN
Drug Alcohol Depend; 2023 Dec; 253():111028. PubMed ID: 38000322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
